Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;21(9):992-1002.
doi: 10.1111/ddg.15144. Epub 2023 Jul 3.

The effect of mogamulizumab on the aberrant T cell population in the peripheral blood - A monocentric retrospective analysis

Janika Gosmann  1 , Annette Bielefeld  2 , Franz-Josef Schmitz  2 , Katrin Schaper-Gerhardt  1   3 , Ralf Gutzmer  1 , Rudolf Stadler  1
Affiliations

The effect of mogamulizumab on the aberrant T cell population in the peripheral blood - A monocentric retrospective analysis

Janika Gosmann et al. J Dtsch Dermatol Ges. 2023 Sep.

Abstract

Background and objectives: The effect of mogamulizumab in cutaneous T-cell lymphoma (CTCL) on T cells (TC) in the peripheral blood and its potential role to navigate treatment intervals are explored.

Methods: We investigated within a retrospective monocentric analysis the effect of mogamulizumab on the CD3+ TC and the aberrant T cell population (TCP), i.e., the CD4+ /CD7- and the CD4+ /CD26- TC, analyzed by flow cytometry.

Results: Thirteen patients with CTCL were included. After four cycles there was a mean reduction of 57% in CD3+ TC, 72% in the CD4+ /CD7- and 75% in the CD4+ /CD26- TCP compared to the individual baseline of each patient. The reduction in CD4+ /CD7+ and CD4+ /CD26+ TC was lower, averaging 54% and 41%. A significant decrease in aberrant TCP was already evident after the first administration. A median plateau of TCP already occurred during the IP. Progressive disease occurred in 5/13 patients without a clear correlation to aberrant TCP.

Conclusions: Already after one dose of mogamulizumab, aberrant TCP and, to a lesser extent, normal TC decrease. We did not observe a clear correlation between TCP and the efficacy of mogamulizumab, but further studies with larger numbers of patients are needed.

Keywords: Mogamulizumab; Mycosis fungoides; Sézary syndrome.

PubMed Disclaimer

References

REFERENCES

    1. European Medicines Agency. Product information Poteligeo. Available from: https://www.ema.europa.eu/en/documents/product-information/poteligeo-epa... [Last accessed December 12, 2022].
    1. Najidh S, Van der Sluijs Gelling AJ, Cozzio A, et al. Immunophenotypic identification and characterization of CTCL tumor cells in blood using standardized flow cytometry: a European multicenter study. European Journal of Cancer, Volume 173S1, Abstractband EORTC CLTG meeting Madrid, September 2022.
    1. Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140(5):419-437.
    1. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
    1. Beygi S, Duran GE, Fernandez-Pol S, et al. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood. 2022;139(26):3732-3736.

MeSH terms